{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:14:43Z","timestamp":1790712883760,"version":"4.1.0"},"reference-count":106,"publisher":"The Japan Society of Coloproctology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2023,4,25]]},"DOI":"10.23922\/jarc.2022-074","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T18:17:14Z","timestamp":1682360234000},"page":"38-51","source":"Crossref","is-referenced-by-count":12,"title":["Recent Advances and Current Management for Desmoid Tumor Associated with Familial Adenomatous Polyposis"],"prefix":"10.23922","volume":"7","author":[{"given":"Kensuke","family":"Kumamoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Kagawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Tomita","sequence":"additional","affiliation":[{"name":"Cancer Treatment Center, Toyonaka Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10009","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Arvanitis ML, Jagelman DG, Fazio VW, et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1990 Aug; 33 (8): 639-42.","DOI":"10.1007\/BF02150736"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bertario L, Presciuttini S, Sala P, et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol. 1994 May-Jun; 10 (3): 225-34.","DOI":"10.1002\/ssu.2980100311"},{"key":"3","unstructured":"3. Fletcher CDM BJ, Hogendoorn PCW, Mertens F, editor. WHO Classification of tumours of soft tissue and bone. Pathology and genetics of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, et al. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011 Jul; 129 (1): 256-61.","DOI":"10.1002\/ijc.25664"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Koskenvuo L, Ristim\u00e4ki A, Lepist\u00f6 A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017 Nov; 116 (6): 716-21.","DOI":"10.1002\/jso.24699"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010 Jun; 49 (6): 560-8.","DOI":"10.1002\/gcc.20766"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Robanus-Maandag E, Bosch C, Amini-Nik S, et al. Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One. 2011 Sep; 6 (9): e24354.","DOI":"10.1371\/journal.pone.0024354"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol. 2001 Apr; 3 (4): 433-8.","DOI":"10.1038\/35070129"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. Gut. 1994 Mar; 35 (3): 377-81.","DOI":"10.1136\/gut.35.3.377"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lotfi AM, Dozois RR, Gordon H, et al. Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis. 1989 Mar; 4 (1): 30-6.","DOI":"10.1007\/BF01648547"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001 Mar; 95 (2): 102-7.","DOI":"10.1002\/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO;2-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwama T, Mishima Y, Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg. 1993 Feb; 217 (2): 101-8.","DOI":"10.1097\/00000658-199302000-00002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, et al. Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 1994 Aug; 74 (4): 1270-4.","DOI":"10.1002\/1097-0142(19940815)74:4<1270::AID-CNCR2820740415>3.0.CO;2-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Clark SK, Neale KF, Landgrebe JC, et al. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999 Sep; 86 (9): 1185-9.","DOI":"10.1046\/j.1365-2168.1999.01222.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Durno C, Monga N, Bapat B, et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol. 2007 Oct; 5 (10): 1190-4.","DOI":"10.1016\/j.cgh.2007.06.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008 Feb; 6 (2): 215-9.","DOI":"10.1016\/j.cgh.2007.11.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer. 2011 Jan; 104 (1): 37-42.","DOI":"10.1038\/sj.bjc.6605997"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Walter T, Zhenzhen Wang C, Guillaud O, et al. Management of desmoid tumours: a large national database of familial adenomatous patients shows a link to colectomy modalities and low efficacy of medical treatments. United European Gastroenterol J. 2017 Aug; 5 (5): 735-41.","DOI":"10.1177\/2050640616678150"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sanchez-Mete L, Ferraresi V, Caterino M, et al. Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series. J Clin Med. 2020 Dec; 9 (12): 4012.","DOI":"10.3390\/jcm9124012"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Inoue Y, Ishida H, Ueno H, et al. The treatment of desmoid tumors associated with familial adenomatous polyposis: the results of a Japanese multicenter observational study. Surg Today. 2017 Oct; 47 (10): 1259-67.","DOI":"10.1007\/s00595-017-1500-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Babaya A, Yamano T, Matsubara T, et al. Long-term clinical outcomes and follow-up status in Japanese patients with familial adenomatous polyposis after radical surgery: a descriptive, retrospective cohort study from a single institute. Int J Colorectal Dis. 2020 Apr; 35 (4): 675-84.","DOI":"10.1007\/s00384-020-03524-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mori Y, Amano K, Chikatani K, et al. Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan. Int J Clin Oncol. 2022 Jun; 27 (6): 1034-42.","DOI":"10.1007\/s10147-022-02146-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Saito Y, Hinoi T, Ueno H, et al. Risk Factors for the Development of Desmoid Tumor After Colectomy in Patients with Familial Adenomatous Polyposis: Multicenter Retrospective Cohort Study in Japan. Ann Surg Oncol. 2016 Aug; 23 (Suppl 4): 559-65.","DOI":"10.1245\/s10434-016-5380-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Konishi T, Ishida H, Ueno H, et al. Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study. Int J Clin Oncol. 2016 Oct; 21 (5): 953-61.","DOI":"10.1007\/s10147-016-0977-x"},{"key":"25","unstructured":"25. Ueno H, Kobayashi H, Konishi T, et al. Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. Int J Clin Oncol. 2016 Aug; 21 (4): 713-22."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Heinimann K, M\u00fcllhaupt B, Weber W, et al. Phenotypic differences in familial adenomatous polyposis based on APC gene mutation status. Gut. 1998 Nov; 43 (5): 675-9.","DOI":"10.1136\/gut.43.5.675"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Friedl W, Caspari R, Sengteller M, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut. 2001 Apr; 48 (4): 515-21.","DOI":"10.1136\/gut.48.4.515"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg. 1996 Nov; 83 (11): 1494-504.","DOI":"10.1002\/bjs.1800831105"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sturt NJ, Clark SK. Current ideas in desmoid tumours. Fam Cancer. 2006 Sep; 5 (3): 275-85; discussion 287-8.","DOI":"10.1007\/s10689-005-5675-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. B\u00e9roud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1996 Jan; 24 (1): 121-4.","DOI":"10.1093\/nar\/24.1.121"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet. 1992 Jul; 1 (4): 229-33.","DOI":"10.1093\/hmg\/1.4.229"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr; 68 (4): 820-3.","DOI":"10.1073\/pnas.68.4.820"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science. 1993 Dec; 262 (5140): 1731-4.","DOI":"10.1126\/science.8259518"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Behrens J, Jerchow BA, W\u00fcrtele M, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998 Apr; 280 (5363): 596-9.","DOI":"10.1126\/science.280.5363.596"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Albuquerque C, Breukel C, van der Luijt R, et al. The &apos;just-right&apos; signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet. 2002 Jun; 11 (13): 1549-60.","DOI":"10.1093\/hmg\/11.13.1549"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson&apos;s &apos;two-hit&apos; hypothesis. Nat Med. 1999 Sep; 5 (9): 1071-5.","DOI":"10.1038\/12511"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007 Feb; 61 (2): 153-61.","DOI":"10.1016\/j.critrevonc.2006.07.004"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009 Oct; 4: 22.","DOI":"10.1186\/1750-1172-4-22"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Latchford A, Volikos E, Johnson V, et al. APC mutations in FAP-associated desmoid tumours are non-random but not &apos;just right&apos;. Hum Mol Genet. 2007 Jan; 16 (1): 78-82.","DOI":"10.1093\/hmg\/ddl442"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995 Mar; 4 (3): 337-40.","DOI":"10.1093\/hmg\/4.3.337"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Walton SJ, Lewis A, Jeffery R, et al. Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours. Oncoscience. 2016 Jun; 3 (5-6): 173-85.","DOI":"10.18632\/oncoscience.312"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Bianchi E, Ruberti S, Rontauroli S, et al. Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. Int J Mol Sci. 2017 Jan; 18 (1): 145.","DOI":"10.3390\/ijms18010145"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Rotelli MT, Refolo MG, Lippolis C, et al. The role of miRNA-133b and its target gene SIRT1 in FAP-derived desmoid tumor. Oncotarget. 2020 Jun; 11 (26): 2484-92.","DOI":"10.18632\/oncotarget.27622"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut. 2004 Dec; 53 (12): 1832-6.","DOI":"10.1136\/gut.2004.042705"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Sinha A, Tekkis PP, Gibbons DC, et al. Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis. 2011 Nov; 13 (11): 1222-9.","DOI":"10.1111\/j.1463-1318.2010.02345.x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Vitellaro M, Sala P, Signoroni S, et al. Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis. Br J Surg. 2014 Apr; 101 (5): 558-65.","DOI":"10.1002\/bjs.9411"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Sinha A, Burns EM, Latchford A, et al. Risk of desmoid formation after laparoscopic versus open colectomy and ileorectal anastomosis for familial adenomatous polyposis. BJS Open. 2018 Aug; 2 (6): 452-5.","DOI":"10.1002\/bjs5.90"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Aelvoet AS, Struik D, Bastiaansen BAJ, et al. Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer. 2022 Jan 13.","DOI":"10.1007\/s10689-022-00288-y"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Xie M, Chen Y, Wei W, et al. Does ileoanal pouch surgery increase the risk of desmoid in patients with familial adenomatous polyposis? Int J Colorectal Dis. 2020 Aug; 35 (8): 1599-605.","DOI":"10.1007\/s00384-020-03578-y"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Elayi E, Manilich E, Church J. Polishing the crystal ball: knowing genotype improves ability to predict desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum. 2009 Oct; 52 (10): 1762-6.","DOI":"10.1007\/DCR.0b013e3181b5518a"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Church J, Berk T, Boman BM, et al. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum. 2005 Aug; 48 (8): 1528-34.","DOI":"10.1007\/s10350-005-0018-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Tomita N, Ishida H, Tanakaya K, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol. 2021 Aug; 26 (8): 1353-419.","DOI":"10.1007\/s10147-021-01881-4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Peterschulte G, Lickfeld T, M\u00f6slein G. Das Desmoid-Problem [The desmoid problem]. Chirurg. 2000 Aug; 71 (8): 894-903.","DOI":"10.1007\/s001040051153"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Desurmont T, Lef\u00e8vre JH, Shields C, et al. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer. 2015 Mar; 14 (1): 31-9.","DOI":"10.1007\/s10689-014-9760-1"},{"key":"55","unstructured":"55. Ishida H, Chikatani K, Mori Y, et al. Diagnosis, treatment, and proposal of the new classification system for the severity of desmoid tumors associated with familial adenomatous polyposis. J Hered Tumors. 2020 Sep; 20 (2): 45-58."},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Koskenvuo L, Ristim\u00e4ki A, Lepist\u00f6 A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017 Nov; 116 (6): 716-21.","DOI":"10.1002\/jso.24699"},{"key":"57","unstructured":"57. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020 Mar; 127: 96-107."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) \/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017 Oct; 28 (10): 2399-408.","DOI":"10.1093\/annonc\/mdx323"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Howard JH, Pollock RE. Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis. Oncol Ther. 2016 Jun; 4 (1): 57-72.","DOI":"10.1007\/s40487-016-0017-z"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Marchis DE ML, Tonelli F, Quaresmini D, et al. Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Res. 2017 Jul; 37 (7): 3357-66.","DOI":"10.21873\/anticanres.11702"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Mart\u00ednez Trufero J, Pajares Bernad I, Torres Ram\u00f3n I, et al. Desmoid-Type Fibromatosis: Who, When, and How to Treat. Curr Treat Options Oncol. 2017 May; 18 (5): 29.","DOI":"10.1007\/s11864-017-0474-0"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Leithner A, Gapp M, Leithner K, et al. Margins in extra-abdominal desmoid tumors: a comparative analysis. J Surg Oncol. 2004 Jun; 86 (3): 152-6.","DOI":"10.1002\/jso.20057"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Iwama T, Kuwabara K, Ushiama M, et al. Identification of somatic APC mutations in recurrent desmoid tumors in a patient with familial adenomatous polyposis to determine actual recurrence of the original tumor or de novo occurrence. Fam Cancer. 2009 Mar; 8 (1): 51-4.","DOI":"10.1007\/s10689-008-9207-7"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008 Apr; 34 (4): 462-8.","DOI":"10.1016\/j.ejso.2007.06.006"},{"key":"65","unstructured":"65. Church JM. Desmoid tumours in patients with familial adenomatous polyposis. Semin Colon Rectal Surg. 1995; 6: 29-32."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May; 328 (18): 1313-6.","DOI":"10.1056\/NEJM199305063281805"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Waddell WR, Gerner RE, Reich MP. Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol. 1983 Mar; 22 (3): 197-211.","DOI":"10.1002\/jso.2930220314"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Belliveau P, Graham AM. Mesenteric desmoid tumor in Gardner&apos;s syndrome treated by sulindac. Dis Colon Rectum. 1984 Jan; 27 (1): 53-4.","DOI":"10.1007\/BF02554079"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Picariello L, Brandi ML, Formigli L, et al. Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms. Eur J Pharmacol. 1998 Oct; 360 (1): 105-12.","DOI":"10.1016\/S0014-2999(98)00665-7"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Jones IT, Jagelman DG, Fazio VW, et al. Desmoid tumors in familial polyposis coli. Ann Surg. 1986 Jul; 204 (1): 94-7.","DOI":"10.1097\/00000658-198607000-00014"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum. 1992 Jan; 35 (1): 29-33.","DOI":"10.1007\/BF02053335"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. McLean MH, Murray GI, Fyfe N, et al. COX-2 expression in sporadic colorectal adenomatous polyps is linked to adenoma characteristics. Histopathology. 2008 Jun; 52 (7): 806-15.","DOI":"10.1111\/j.1365-2559.2008.03038.x"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Poon R, Smits R, Li C, et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene. 2001 Jan; 20 (4): 451-60.","DOI":"10.1038\/sj.onc.1204107"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun; 342 (26): 1946-52.","DOI":"10.1056\/NEJM200006293422603"},{"key":"75","unstructured":"75. Colombo C, Foo WC, Whiting D, et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol. 2012 May; 27 (5): 641-9."},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. H\u00e4yry P, Reitamo JJ, T\u00f6tterman S, et al. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982 Jun; 77 (6): 674-80.","DOI":"10.1093\/ajcp\/77.6.674"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol. 2005 Nov; 58 (11): 1152-6.","DOI":"10.1136\/jcp.2005.026278"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Paterni I, Granchi C, Katzenellenbogen JA, et al. Estrogen receptors alpha (ER\u03b1) and beta (ER\u03b2): subtype-selective ligands and clinical potential. Steroids. 2014 Nov; 90: 13-29.","DOI":"10.1016\/j.steroids.2014.06.012"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Santti K, Ihalainen H, R\u00f6nty M, et al. Estrogen receptor beta expression correlates with proliferation in desmoid tumors. J Surg Oncol. 2019 Jun; 119 (7): 873-9.","DOI":"10.1002\/jso.25407"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Brooks MD, Ebbs SR, Colletta AA, et al. Desmoid tumours treated with triphenylethylenes. Eur J Cancer. 1992 May; 28A (6-7): 1014-8.","DOI":"10.1016\/0959-8049(92)90445-8"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004 Feb; 100 (3): 612-20.","DOI":"10.1002\/cncr.11937"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. de Camargo VP, Keohan ML, D&apos;Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010 May; 116 (9): 2258-65.","DOI":"10.1002\/cncr.25089"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Muchmore DB. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist. 2000 Oct; 5 (5): 388-92.","DOI":"10.1634\/theoncologist.5-5-388"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Tonelli F, Ficari F, Valanzano R, et al. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori. 2003 Jul-Aug; 89 (4): 391-6.","DOI":"10.1177\/030089160308900408"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Quast DR, Schneider R, Burdzik E, et al. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer. 2016 Jan; 15 (1): 31-40.","DOI":"10.1007\/s10689-015-9830-z"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Lynch HT, Fitzgibbons R Jr, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner&apos;s syndrome. Dis Colon Rectum. 1994 Mar; 37 (3): 260-7.","DOI":"10.1007\/BF02048164"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006 Jan; 24 (1): 102-5.","DOI":"10.1200\/JCO.2005.02.1923"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Ezumi K, Yamamoto H, Takemasa I, et al. Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Jpn J Clin Oncol. 2008 Mar; 38 (3): 222-6.","DOI":"10.1093\/jjco\/hyn004"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001 Sep; 92 (5): 1259-64.","DOI":"10.1002\/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Palassini E, Frezza AM, Mariani L, et al. Long-term Efficacy of methotrexate plus vinblastine\/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J. 2017 Mar\/Apr; 23 (2): 86-91.","DOI":"10.1097\/PPO.0000000000000254"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Skapek SX, Ferguson WS, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb; 25 (5): 501-6.","DOI":"10.1200\/JCO.2006.08.2966"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Napolitano A, Provenzano S, Colombo C, et al. Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open. 2020 Jan; 5 (1): e000604.","DOI":"10.1136\/esmoopen-2019-000604"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug; 347 (7): 472-80.","DOI":"10.1056\/NEJMoa020461"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006 Mar; 24 (7): 1195-203.","DOI":"10.1200\/JCO.2005.04.0717"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor\/deep fibromatosis. Clin Cancer Res. 2011 Jun; 17 (12): 4082-90.","DOI":"10.1158\/1078-0432.CCR-10-3322"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec; 379 (25): 2417-28.","DOI":"10.1056\/NEJMoa1805052"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019 Sep; 20 (9): 1263-72.","DOI":"10.1016\/S1470-2045(19)30276-1"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Matono H, Tamiya S, Yokoyama R, et al. Abnormalities of the Wnt\/\u03b2-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between \u03b2-catenin widespread nuclear expression and VEGF overexpression. Histopathology. 2011 Sep; 59 (3): 368-75.","DOI":"10.1111\/j.1365-2559.2011.03945.x"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Janegova A, Hlavata Z, Mihok L, et al. Immunohistochemical evaluation of potential molecular targets of desmoid-type fibromatosis. Pol J Pathol. 2021; 72 (3): 252-60.","DOI":"10.5114\/pjp.2021.111776"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May; 379 (9829): 1879-86.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Crump CJ, Johnson DS, Li YM. Development and mechanism of \u03b3-secretase modulators for Alzheimer&apos;s disease. Biochemistry. 2013 May; 52 (19): 3197-216.","DOI":"10.1021\/bi400377p"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi&apos;s sarcoma tumor cells. Oncogene. 2005 Sep; 24 (42): 6333-44.","DOI":"10.1038\/sj.onc.1208783"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Wang M, Wu L, Wang L, et al. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun. 2010 Feb; 393 (1): 144-9.","DOI":"10.1016\/j.bbrc.2010.01.103"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A. 2009 Apr; 106 (15): 6315-20.","DOI":"10.1073\/pnas.0813221106"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Yabuuchi S, Pai SG, Campbell NR, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett. 2013 Jul; 335 (1): 41-51.","DOI":"10.1016\/j.canlet.2013.01.054"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Kummar S, O&apos;Sullivan Coyne G, Do KT, et al. Clinical Activity of the \u03b3-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 May; 35 (14): 1561-9.","DOI":"10.1200\/JCO.2016.71.1994"}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/7\/2\/7_2022-074\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:57:24Z","timestamp":1682729844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/7\/2\/7_2022-074\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2022-074","relation":{},"ISSN":["2432-3853"],"issn-type":[{"value":"2432-3853","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"article-number":"2022-074"}}